We could not find any results for:
Make sure your spelling is correct or try broadening your search.
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbo... GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection. Show more
Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) to be reported in Q2 2024 New Drug Application (NDA) for uproleselan to be...
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at...
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44th Annual Health Care Conference in...
GlycoMimetics, Inc. (the βCompanyβ) (NASDAQ:GLYC) today announced that the Compensation Committee of the Companyβs Board of Directors approved the grant on February 6, 2024 of a non-qualified...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.41 | -15.953307393 | 2.57 | 2.57 | 2.14 | 632924 | 2.30541421 | CS |
4 | -0.87 | -28.7128712871 | 3.03 | 3.18 | 2.14 | 546637 | 2.65358378 | CS |
12 | -0.91 | -29.6416938111 | 3.07 | 3.5 | 2.14 | 393107 | 2.83503395 | CS |
26 | 0.75 | 53.1914893617 | 1.41 | 3.5299 | 1.11 | 310228 | 2.63579377 | CS |
52 | 0.6 | 38.4615384615 | 1.56 | 3.5299 | 1.11 | 241226 | 2.2993476 | CS |
156 | -0.43 | -16.6023166023 | 2.59 | 4.16 | 0.51 | 431021 | 2.11447638 | CS |
260 | -9.8 | -81.9397993311 | 11.96 | 13.41 | 0.51 | 470596 | 3.06781189 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions